Study of first single-shot vaccine begins in US

Johnson & Johnson is beginning a huge final study to try to prove if a single-dose COVID-19 vaccine can protect against the virus. The study starting Wednesday will be one of the world's largest coronavirus vaccine studies so far, testing the shot in 60,000 volunteers in the U.S., South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. "The 60,000 people will allow us to recruit more diversity globally," said Dr. Paul Stoffels, J&J's chief scientific officer. J&Js vaccine is made with slightly different technology than others in late-stage testing, modeled on an Ebola vaccine the company created. Unlike the other three vaccines that started late-stage testing in the U.S., it requires only one shot, not two. Despite a later start to testing than some of its competitors, Dr. "It's a single dose which could be very important for emergency use. We will later on test the booster dose, and we will test boosters later on, but the efficacy in the phase 1 showed the single dose could be sufficient to protect people for a long time," said Stoffels, who told reporters that the study was large enough to yield answers possibly by early next year. A handful of other vaccines in the U.S. — including shots made by Moderna Inc. and Pfizer Inc. — and others in other countries are already in final-stage testing. Hopes are high that answers about at least one candidate being tested in the U.S. could come by year's end, maybe sooner. U.S. health officials insist the race for a vaccine isn't cutting corners. "We want to do everything we can without sacrificing safety or efficacy — we're not going to do that — to make sure that we end up with vaccines that are going to save lives," " Dr. Francis Collins, director of the National Institutes of Health, told reporters. J&Js vaccine is made with slightly different technology than others in late-stage testing, modeled on an Ebola vaccine the company created. Unlike the other three vaccines that started late-stage testing in the U.S., it requires only one shot, not two. Despite a later start to testing than some of its competitor. "It's a single dose which could be very important for emergency use. We will later on test the booster dose, and we will test boosters later on, but the efficacy in the phase 1 showed the single dose could be sufficient to protect people for a long time," said Stoffels, who told reporters that the study was large enough to yield answers possibly by early next year. But many vaccine specialists question whether the Food and Drug Administration will stick to that goal under intense pressure from the Trump administration. President Donald Trump has consistently presented a faster timeline for a new vaccine than experts say is adequate to fully test the candidates. Trump on Wednesday tweeted the link to a news report about the Johnson & Johnson study and said the FDA "must move quickly!" Meanwhile, testing of still another experimental vaccine, made by AstraZeneca, remains on hold in the U.S. as officials examine a safety question, even though studies have resumed in other countries. Earlier this week, Vice President Mike Pence urged state governors to "do your part to build public confidence that it will be a safe and effective vaccine." The Centers for Disease Control and Prevention wants states to get ready now to roll out vaccinations, which will present enormous logistical challenges. On Wednesday the CDC was set to announce distribution of $200 million in congressionally approved funds to help begin setting up operations. Health and Human Services Secretary Alex Azar said the COVID-19 vaccine campaign will build on longstanding cooperation between the federal government and the states on immunizations. (Representative Image)

Advertisement

Study of first single-shot vaccine begins in US

Johnson & Johnson is beginning a huge final study to try to prove if a single-dose COVID-19 vaccine can protect against the virus.

Advertisement